In line with our findings, intratumoral M2 macrophage levels as well as myeloid cell infiltrate levels (monocytes, M0, M1, and M2 macrophages) showed a trend toward elevated levels in NR glioblastoma patients before anti-PD-1 therapy (Fig. 5e), supporting the hypothesis that suppressive myeloid cell subsets impair the induction of antitumor T cell responses by ICB therapy. Here, PDCD1 is linked to glioblastoma.